about
Atrogin-1 deficiency promotes cardiomyopathy and premature death via impaired autophagy.Role of neuroinflammation in hypertension-induced brain amyloid pathology.Protein kinase Cθ is required for cardiomyocyte survival and cardiac remodeling.Nebulette knockout mice have normal cardiac function, but show Z-line widening and up-regulation of cardiac stress markers.DNA hydroxymethylation controls cardiomyocyte gene expression in development and hypertrophy.Genome-wide analysis of histone marks identifying an epigenetic signature of promoters and enhancers underlying cardiac hypertrophy.T cell costimulation blockade blunts pressure overload-induced heart failure.Bioinspired negatively charged calcium phosphate nanocarriers for cardiac delivery of MicroRNAs.MicroRNA-133 modulates the β1-adrenergic receptor transduction cascade.Growth hormone-releasing hormone attenuates cardiac hypertrophy and improves heart function in pressure overload-induced heart failure.Distinct effects of leukocyte and cardiac phosphoinositide 3-kinase γ activity in pressure overload-induced cardiac failure.Tumor necrosis factor-alpha mediates hemolysis-induced vasoconstriction and the cerebral vasospasm evoked by subarachnoid hemorrhage.Histone Methyltransferase G9a Is Required for Cardiomyocyte Homeostasis and Hypertrophy.Beta-amyloid deposition in brain is enhanced in mouse models of arterial hypertension.Inhalation of peptide-loaded nanoparticles improves heart failure.An autofluorescence-based method for the isolation of highly purified ventricular cardiomyocytes.Content of mitochondrial calcium uniporter (MCU) in cardiomyocytes is regulated by microRNA-1 in physiologic and pathologic hypertrophy.Peptidomimetic Targeting of Cavβ2 Overcomes Dysregulation of the L-Type Calcium Channel Density and Recovers Cardiac Function.Expression and function of IL-1R8 (TIR8/SIGIRR): a regulatory member of the IL-1 receptor family in platelets.UHRF1 epigenetically orchestrates smooth muscle cell plasticity in arterial disease.Nebivolol induces nitric oxide release in the heart through inducible nitric oxide synthase activation.
P50
Q33685877-625D5DEE-86BB-437C-8348-0E112EFDE458Q33723685-F4F47972-57F1-47C8-BE31-E703F5CC4B92Q34545363-EDD36858-16C8-44F5-A232-DA19C9C6798AQ36048963-41CC34FD-3BCA-48B3-93A1-E355BCEB6FAFQ37157067-589F832D-1EDD-483C-B96C-C6404CCAD6BBQ37395232-5A7EEE4C-BA57-4F1B-9780-6E1D25C670C5Q37690286-AF9E9D4F-2EA9-4FD1-B74C-30ADC72785C1Q38786123-92541CC0-DDB8-4AA3-BA0F-65FF5B30BF39Q40036242-4F956172-23C5-4FEE-AED6-6CD3B7FF7D2FQ43455909-256C1A89-BFF3-437A-B4B5-F935138DD08FQ45103986-08D9717B-6F0C-467B-A88F-8FDFA11584E8Q45995798-9C9C06ED-92FB-4411-BADA-0847E428DCF6Q47989181-0DD14925-E4E6-4966-A12A-027E22B2BB91Q48087176-06219A5E-8EAB-4E34-BA67-D83D25F1C1DCQ48223842-BEB99547-5AC9-4D1D-9F15-C05811CFA884Q49824944-9B8A1A7E-E53B-4DCD-AD7F-5F604A5125BEQ50089772-7A78DBC2-AD31-4DE4-B87F-74986B4D9697Q51597916-9D34349E-FA3A-448F-90AD-DB40B2D5A17FQ51704486-233A945B-0B02-487E-87DF-1D9851E06B9CQ52725468-3A3FAA11-13A8-42CE-98EF-DC2EC7FF68ACQ54323997-649F199D-E1FB-4492-970B-72097E6422BA
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Pierluigi Carullo
@ast
Pierluigi Carullo
@en
Pierluigi Carullo
@es
Pierluigi Carullo
@nl
type
label
Pierluigi Carullo
@ast
Pierluigi Carullo
@en
Pierluigi Carullo
@es
Pierluigi Carullo
@nl
prefLabel
Pierluigi Carullo
@ast
Pierluigi Carullo
@en
Pierluigi Carullo
@es
Pierluigi Carullo
@nl
P106
P1153
21833401500
P31
P496
0000-0003-0812-7770